Clinical TrialsManagement noted that clinical engagement remained robust for the ongoing Phase IIa CBeyond trial and that the three safety reviews conducted by the Data Safety Monitoring Committee had not raised concerns.
Financial PositionThe company ended 2024 with $68.4 million in cash, which is expected to fund operations through at least the first quarter of 2027.
PartnershipsThe collaboration with Arecor Therapeutics could enable testing higher doses of nimacimab, potentially allowing for once-monthly dosing during future clinical development.